Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Compass Therapeutics
Compass Therapeutics
Centre Hospitalier Universitaire de Nice
Pfizer
H. Lee Moffitt Cancer Center and Research Institute
Adaptimmune
Pierre Fabre Medicament
Abramson Cancer Center at Penn Medicine
Vedanta Biosciences, Inc.
Eisai Inc.
Dana-Farber Cancer Institute
Anaveon AG
Incyte Corporation
Incyte Corporation
Leap Therapeutics, Inc.
Biogen
Biogen
Grupo Español Multidisciplinar de Melanoma
Scholar Rock, Inc.
Cedars-Sinai Medical Center
National Cancer Institute (NCI)
Actelion
Altor BioScience
National Cancer Institute (NCI)
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Pfizer
National Cancer Institute (NCI)
Cedars-Sinai Medical Center
Rockefeller University
Eli Lilly and Company
Memorial Sloan Kettering Cancer Center
University of California, San Francisco
M.D. Anderson Cancer Center
NextCure, Inc.
Centre Hospitalier Universitaire de Nice
Rutgers, The State University of New Jersey
Perspective Therapeutics
Eastern Cooperative Oncology Group
Providence Health & Services
Nektar Therapeutics
Herlev Hospital
Quadriga Biosciences, Inc.
Grupo Español Multidisciplinar de Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Nantes University Hospital
Bristol-Myers Squibb
Pfizer
University of Kansas Medical Center
M.D. Anderson Cancer Center
Northwestern University
Eisai Inc.